Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.68 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138472 | 1.00 | CHRM3 (0.68) | CHRM3CHRM2CHRM1PTGS2APOBEC3A | |
| SCHEMBL2842262 | 0.85 | CHRM3 (0.67) | CHRM3CHRM2CHRM1PTGS2APOBEC3A | |
| SCHEMBL2842263 | 0.85 | CHRM3 (0.67) | CHRM3CHRM2CHRM1PTGS2APOBEC3A | |
| SCHEMBL3910006 | 0.84 | CHRM3 (0.47) | CHRM3PTGS2APOBEC3AAPOBEC3GALDH1A1 | |
| Bromide SCHEMBL141730 | 0.82 | CHRM3 (1.00) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL4166137 | 0.77 | CHRM3 (0.88) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL4166138 | 0.77 | CHRM3 (0.88) | CHRM3CHRM2CHRM1APOBEC3AAPOBEC3G | |
| SCHEMBL9469983 | 0.77 | ACHE (0.39) | APOBEC3AAPOBEC3GALDH1A1CYP2C9 | |
| SCHEMBL5990950 | 0.74 | CHRM2 (0.40) | CHRM3CHRM2CHRM1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5990945 | 0.74 | CHRM2 (0.40) | CHRM3CHRM2CHRM1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-17 | — | — | US | disclosed |
| US-20220324875-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-13 | — | — | US | disclosed |
| EP-3612536-B1 | OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-10793559-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| EP-3414228-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| US-20200071311-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20070043007-A1 | Specific glucocorticosteroid compounds having anti-inflammatory activity | GLAXO GROUP LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20060293298-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| US-20060247219-A1 | Specific glucocorticosteriod compound having anti-inflamatory activity | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | US | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006108699-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060178395-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| WO-2006062883-A2 | MEDICAL COMBINATIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006015870-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| US-20060019964-A1 | Antiallergens; antiinflammatory agents; rhinitis; serotonin receptor antagonist | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793559-B2 | Chemical compounds | PIK3CA, PIK3CD, PIK3C2B | CHRM3 3771/4885CHRM2 4440/4885CHRM1 4169/4885 |
| US-10624898-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | CHRM3 4030/4885CHRM2 4500/4885CHRM1 4207/4885 |
| US-20220324875-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | CHRM3 4065/4885CHRM2 4667/4885CHRM1 4329/4885 |
| US-20060293298-A1 | Compounds | NQO1, OPRM1, CAT | CHRM3 1901/4885CHRM2 2314/4885CHRM1 1558/4885 |
| US-10946025-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | CHRM3 4030/4885CHRM2 4500/4885CHRM1 4207/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | CHRM3 3764/4885CHRM2 4617/4885CHRM1 4447/4885 |
| US-20060178395-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885 |
| US-20060247219-A1 | Specific glucocorticosteriod compound having anti-inflamatory activity | NR3C1, NR3C2, MC2R | CHRM3 225/4885CHRM2 280/4885CHRM1 135/4885 |
| US-20200071311-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | CHRM3 3771/4885CHRM2 4440/4885CHRM1 4169/4885 |
| US-20070043007-A1 | Specific glucocorticosteroid compounds having anti-inflammatory activity | NR3C2, NR3C1, NR5A1 | CHRM3 737/4885CHRM2 1488/4885CHRM1 1415/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | CHRM3 3446/4885CHRM2 4347/4885CHRM1 4288/4885 |
| US-20060019964-A1 | Antiallergens; antiinflammatory agents; rhinitis; serotonin receptor antagonist | HRH2, HRH4, HRH1 | CHRM3 734/4885CHRM2 1361/4885CHRM1 1028/4885 |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | CDK3, CDK13, AKT3 | CHRM3 1182/4885CHRM2 1917/4885CHRM1 1223/4885 |
| US-20200206237-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | CHRM3 4226/4885CHRM2 4504/4885CHRM1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.